Video

  • 20 June 2016

    BIO-Europe Spring 2016: RMI says it has USD 200 million already under management

    BIO-Europe Spring 2016: RMI says it has USD 200 million already under management

    EBD Group

    Maxim Gorbachev, a partner and portfolio manager at RusnanoMedInvest (RMI) speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio about Russia’s and Eastern Europe’s largest venture capital company, specializing in innovative developments in the field of pharmaceuticals and biotechnology. 

  • 22 June 2015

    Leonid Melamed: uncertainty period is the best time to make important tactical and strategical decisions

    Leonid Melamed: uncertainty period is the best time to make important tactical and strategical decisions

    June 25, 2015, Vedomosti newspaper office will host a FocusForum Conference in Moscow with a leading participation of Leonid Melamed, the Chairman of Team Drive, member of the Board of Directors of NovaMedica, RMI Partners and Doctor Ryadom. The conference’s goal is to gather experts and share ideas and valuable experience in the time of business challenges. In his video interview to Vedomosti, Leonid explained his vision of the company management tasks in the period of uncertainty. 

  • 16 October 2014

    Dr. Evgeny Zaytsev, Managing Partner, RMI Partners: Exits in biotech usually have a very long tail of payments

    Dr. Evgeny Zaytsev, Managing Partner, RMI Partners: Exits in biotech usually have a very long tail of payments

    As part of the Panel Discussion “Optimal Strategies and Exit Models for Venture Investors” held during 3rd Moscow International Forum for Innovative Development “Open Innovations” Evgeny Zaytsev shared his experience of various exit models from venture investments in biotech.

  • 23 May 2014

    SPIEF2014. Leonid Melamed: Apparently, the one, who shall benefit from the development of public-private partnerships, is the patient

    SPIEF2014. Leonid Melamed: Apparently, the one, who shall benefit from the development of public-private partnerships, is the patient

    In general terms, engagement of private companies in the healthcare system on a competitive basis shall result in the price optimization and improvement of the quality of medical services provided and pharmaceuticals delivered to patients, Leonid Melamed, Chairman of the Board, Team Drive; Member of the Board of Directors, RusnanoMedInvest and NovaMedica said on Friday at St. Petersburg SPIEF2014.

  • 12 February 2013

    Brian Dovey, Domain Associates LLC -  speaking about VC/Rusnanotech 2011

    Brian Dovey, Domain Associates LLC - speaking about VC/Rusnanotech 2011

    Brian Dovey, Partner, Domain Associates LLC (one of the first venture capital firms to exclusively invest in the life sciences sector) -  speaking about VC (Rusnanotech 2011)

  • 21 June 2012

    St. Petersburg International Economic Forum

    St. Petersburg International Economic Forum

    Leonid Melamed: Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets

All Partners

All Portfolio

MEDIA CENTER

  • Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer and NovaMedica Complete Strategic Partnership Agreement for the Technology Transfer of 30 Key Medicines

    Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.

All news